---
title: "Genor Biopharma Secures NMPA Approval for Lerociclib to Treat Advanced Breast Cancer"
description: "Genor Biopharma Holdings Ltd. has received approval from the China National Medical Products Administration (NMPA) for its drug Lerociclib (GB491), a selective CDK4/6 inhibitor. This drug is intended "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/242355522.md"
published_at: "2025-05-29T08:59:48.000Z"
---

# Genor Biopharma Secures NMPA Approval for Lerociclib to Treat Advanced Breast Cancer

> Genor Biopharma Holdings Ltd. has received approval from the China National Medical Products Administration (NMPA) for its drug Lerociclib (GB491), a selective CDK4/6 inhibitor. This drug is intended for adult patients with HR+/HER2- locally advanced or metastatic breast cancer, to be used with an aromatase inhibitor or fulvestrant. This approval marks a significant achievement for Genor Biopharma and highlights its collaboration with G1 Therapeutics Inc.

Genor Biopharma Holdings Ltd. has announced that the China National Medical Products Administration (NMPA) has granted approval for the new drug application of Lerociclib (GB491). This novel, highly potent, selective oral bioavailable cyclin-dependent kinases 4 and 6 inhibitor (CDK4/6i) has been co-developed by Genor Biopharma and G1 Therapeutics Inc. It is designed for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer. Lerociclib will be used in combination with an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant in patients whose disease has progressed following endocrine therapy. This approval represents a significant milestone for Genor Biopharma and showcases the successful collaboration with G1 Therapeutics Inc.

### Related Stocks

- [06998.HK - EDDING GENOR](https://longbridge.com/en/quote/06998.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Edding Genor Group Holdings Repurchases 7,855,500 Shares for HKD 1,450 in HKEX Filing | Edding Genor Group Holdings Ltd. has repurchased 7,855,500 shares for a total of HKD 1,450, as disclosed in a filing wit | [Link](https://longbridge.com/en/news/275613176.md) |
| Shootin' the Bull about wave 5 of 5 of B | Shootin' the Bull about wave 5 of 5 of B | [Link](https://longbridge.com/en/news/276266924.md) |
| Ence To Cut 44 Jobs At Navia Biofactory By 2027 | Ence Energia y Celulosa SA :REACHES AGREEMENT ON COLLECTIVE DISMISSAL AT NAVIA BIOFACTORYAGREEMENT INCLUDES TERMINATION  | [Link](https://longbridge.com/en/news/276430844.md) |
| CICC Reaffirms Their Buy Rating on Suzhou Ribo Life Science Co., Ltd. Class H (6938) | In a report released yesterday, from CICC maintained a Buy rating on Suzhou Ribo Life Science Co., Ltd. Class H, with a  | [Link](https://longbridge.com/en/news/276199846.md) |
| Metabiomed To Cancel 2.7 Billion Won Worth Of Own Shares | Metabiomed Co Ltd :METABIOMED: TO CANCEL 2.7 BILLION WON WORTH OF OWN SHARES | [Link](https://longbridge.com/en/news/276408478.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.